STATUS DECISION OF CONTROLLED
AND NON-CONTROLLED SUBSTANCE(S)

Substance:  Rimonabant (a.k.a. SR 141716A)

Based on the current information available to the Office of Controlled Substances, it appears that the above substance is:

Controlled   ☐
Not Controlled  X

under the schedules of the *Controlled Drugs and Substances Act* (CDSA) for the following reason(s):

- Rimonabant is not similar to any substance listed on the schedules to the CDSA. Status decisions have been made on several other cannabinoid receptor agonists and antagonists. Cannabinoid receptor agonists have been declared to be included within item 1 of Schedule II to the CDSA by virtue of being “similar synthetic preparations.” Cannabinoid receptor antagonists have been declared to fall outside item 1 of Schedule II to the CDSA.

Supporting document(s) attached: Drug Status Report by Mr. LeBelle

Prepared by: ___________________________      Date:   Sept. 28, 2006
Xiao Peng Feng

Drug Status Report by:  Mr. M. LeBelle      Date:   Sept. 28, 2006

Approved by: ___________________________  Date:   __________
DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES
Drug Status Report

**Drug:** Rimonabant

**Drug Name Status:** Rimonabant is the proper name (INN; USAN)

**Chemical Name:**
5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide

**Other Names:** SR 141716A

**Chemical structure:**

![Chemical Structure](image)

**Molecular Formula:** C\(_{22}\)H\(_{21}\)Cl\(_3\)N\(_4\)O

**Pharmacological class / Application:** Cannabinoid (CB1) receptor antagonist

**International status:**

US: The substance is not listed on the schedules to the US Controlled Substances Act and is not mentioned on the DEA website.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control. The drug is not listed on the Green List - List of Psychotropic Substances under International Control.

Canadian Status: Rimonabant is not similar to any substance listed on the schedules to the CDSA. Status decisions have been made on several other cannabinoid receptor agonists and antagonists. See decisions for anandamide; methanandamide; WIN 555212; JWH 015; O-2050, SR 141716A, AM630 and AM251. Cannabinoid receptor agonists have been declared to be included within item 1 of Schedule II to the CDSA by virtue of being “similar synthetic preparations.” Cannabinoid receptor antagonists have been declared to fall outside item 1 of Schedule II to the CDSA.

Recommendation: Rimonabant is not included in the schedules to the CDSA and is not a controlled substance.